“Efficacy, Durability, And Retreatment Outcomes Of Risankizumab In Moderate To Severe Plaque Psoriasis: Results From The Phase 3 Immhance Trial” (2016) Journal of Carcinogenesis, 15(1). doi:10.64149/.